Advertisement

AAPS PharmSciTech

, 10:808 | Cite as

Nanoemulsion as a Potential Ophthalmic Delivery System for Dorzolamide Hydrochloride

  • Hussein O. AmmarEmail author
  • H. A. Salama
  • M. Ghorab
  • A. A. Mahmoud
Research Article

Abstract

Dilutable nanoemulsions are potent drug delivery vehicles for ophthalmic use due to their numerous advantages as sustained effect and high ability of drug penetration into the deeper layers of the ocular structure and the aqueous humor. The aim of this article was to formulate the antiglaucoma drug dorzolamide hydrochloride as ocular nanoemulsion of high therapeutic efficacy and prolonged effect. Thirty-six systems consisting of different oils, surfactants, and cosurfactants were prepared and their pseudoternary-phase diagrams were constructed by water titration method. Seventeen dorzolamide hydrochloride nanoemulsions were prepared and evaluated for their physicochemical and drug release properties. These nanoemulsions showed acceptable physicochemical properties and exhibited slow drug release. Draize rabbit eye irritation test and histological examination were carried out for those preparations exhibiting superior properties and revealed that they were nonirritant. Biological evaluation of dorzolamide hydrochloride nanoemulsions on normotensive albino rabbits indicated that these products had higher therapeutic efficacy, faster onset of action, and prolonged effect relative to either drug solution or the market product. Formulation of dorzolamide hydrochloride in a nanoemulsion form offers, thus, a more intensive treatment of glaucoma, a decrease in the number of applications per day, and a better patient compliance compared to conventional eye drops.

Key words

dorzolamide hydrochloride glaucoma nanoemulsion pharmacodynamic physicochemical characterization 

Notes

Acknowledgements

We gratefully appreciate the generous supply of dorzolamide hydrochloride by Jamjoom Pharma, Jeddah, KSA and the kind help for assessment of the ocular irritation test by Dr. Maali A. Halim, Faculty of Medicine, Cairo University. We also acknowledge the financial support provided by the National Research Center, Egypt.

References

  1. 1.
    Hughes PM, Mitra AK. Overview of ocular drug delivery and iatrogenic ocular cytopathologies. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker; 1993. p. 1–27.Google Scholar
  2. 2.
    Patton TF, Robinson JR. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes. J Pharm Sci. 1976;65:1295–301.PubMedCrossRefGoogle Scholar
  3. 3.
    Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability II: evaluation of pilocarpine. J Pharm Sci. 1977;66:1222–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Chein YW, Cabana BE, Mares SE. Ocular controlled release drug administration. In: Chein YW, editor. Novel drug delivery systems; fundamentals, development concepts, biomedical assessments (drugs and the pharmaceutical sciences), vol. 14. New York: Marcel Dekker; 1982. p. 13–55.Google Scholar
  5. 5.
    Middleton DL, Leung SS, Robinson JR. Ocular bioadhesive delivery systems. In: Lenaerts V, Gurny R, editors. Bioadhesive drug delivery systems. Boca Raton: CRC; 1990. p. 179–202.Google Scholar
  6. 6.
    Desai SD, Blanchard J. Ocular drug formulation and delivery. In: Swarbick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology, vol. 11. New York: Marcel Dekker; 1994. p. 43–75.Google Scholar
  7. 7.
    Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. Topical use of chitosan in ophthalmology: tolerance, assessment and evaluation of precorneal retention. Int J Pharm. 1999;180:185–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Munier A, Gunning T, Kenny D, O’Keefe M. Causes of blindness in the adult population of the Republic of Ireland. Br J Ophthalmol. 1998;82:630–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Blomdahl S, Calissendorff BM, Tengrowth B, Wallin O. Blindness in glaucoma patients. Acta Ophthalmol (Copenh). 1997;75:589–91.Google Scholar
  10. 10.
    Kaur IP, Smitha R, Aggarwal D, Kapil M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm. 2002;248:1–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs. 2000;59:411–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Maren TH. The development of topical carbonic anhydrase inhibitors. Glaucoma. 1995;4:49–62.Google Scholar
  13. 13.
    Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996;12:363–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19:87–112.PubMedCrossRefGoogle Scholar
  15. 15.
    Sigurdsson HH, Stefansson E, Gudmundsdottir E, Eysteinsson T, Thorsteinsdottir M, Loftsson T. Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J Control Release. 2005;102:255–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Quint MP, Grove J, Thomas SM. Dorzolamide hydrochloride. In: Brittain HG, editor. Analytical profiles of drug substances and excipients, vol. 26. New York: Academic; 1999. p. 283–316.Google Scholar
  17. 17.
    Rusk C, Sharpe E, Laurence J, Polis A, Adamsons I. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide comparison study group. Clin Ther. 1998;20:454–66.PubMedCrossRefGoogle Scholar
  18. 18.
    Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S141–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Salminen L. Review: systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol Ther. 1990;6:243–9.CrossRefGoogle Scholar
  20. 20.
    Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Arici MK, Arici DS, Topalkara A, Guler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Experiment Ophthalmol. 2000;28:113–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Konowal A, Morrison JC, Brown SV, Cooke DL, Maguire LJ, Verdier DV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Silva-Cunha A, Fialho SL, Carneiro LB, Oréfice F. Microemulsões como veículos de drogas para administração ocular tópica. Arq Bras Oftalmol. 2003;66:385–91.Google Scholar
  24. 24.
    Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM. W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention. J Control Release. 2006;111:145–52.PubMedCrossRefGoogle Scholar
  25. 25.
    Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21:15–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Garti N, Aserin A, Tiunova I, Fanun MA. DSC study of water behavior in water-in-oil microemulsions stabilized by sucrose esters and butanol. Colloids Surf A Physicochem Eng Asp. 2000;170:1–18.CrossRefGoogle Scholar
  27. 27.
    Moreno MA, Ballesteros MP, Frutos P. Lecithin-based oil-in-water microemulsions for parenteral use: pseudoternary phase diagrams, characterization and toxicity studies. J Pharm Sci. 2003;92:1428–37.PubMedCrossRefGoogle Scholar
  28. 28.
    Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66:227–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm. 2001;229:29–36.PubMedCrossRefGoogle Scholar
  30. 30.
    Wu C, Qi H, Chen W, Huang C, Su C, Li W, et al. Preparation and evaluation of a carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi. 2007;127:183–91.PubMedCrossRefGoogle Scholar
  31. 31.
    Khan KA, Rhodes CT. Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv. 1972;47:594–607.PubMedGoogle Scholar
  32. 32.
    Draize JH, Woodard G, Calvey HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377–90.Google Scholar
  33. 33.
    Hughes WFJ. The tolerance of rabbit cornea for various chemical substances. Bull Johns Hopkins Hosp. 1948;82:338–49.PubMedGoogle Scholar
  34. 34.
    Laillier J, Plazonnet B, Le Douarec JC. Evaluation of an objective method of studying eye irritation. Proc Eur Soc Toxicol. 1976;17:336–50.Google Scholar
  35. 35.
    Conquet P, Durand G, Laillier J, Plazonnet B. Evaluation of ocular eye irritation in the rabbit: objective versus subjective assessment. Tox App Pharmacol. 1977;39:129–39.CrossRefGoogle Scholar
  36. 36.
    Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm. 2005;301:121–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Alany RG, Tucker IG, Davies NM, Rades T. Characterizing colloidal structures of pseudoternary phase diagrams formed by oil/water/amphiphile systems. Drug Dev Ind Pharm. 2001;27:31–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Chemicals BF. Cremophor® EL. Technical leaflet, ME 074 e. Ludwigshafen: BASF Fine Chemicals; 1997.Google Scholar
  39. 39.
    Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212:233–46.PubMedCrossRefGoogle Scholar
  40. 40.
    Grant WM, Schuman JS. Toxicology of the eye. 4th ed. Springfield: Charles C. Thomas; 1993.Google Scholar
  41. 41.
    Bietti GB, Virno M, Pecori-Giraldi J. Propylene glycol: a new osmotic agent for ophthalmic uses. Doc Ophthalmol. 1973;34:77–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Tamilvanan S, Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm. 2004;58:357–68.PubMedCrossRefGoogle Scholar
  43. 43.
    Aboofazeli R, Lawrence MJ. Investigations into the formation and characterization of phospholipid microemulsions. II. Pseudo-ternary phase diagrams of systems containing water–lecithin–isopropyl myristate and alcohol: influence of purity of lecithin. Int J Pharm. 1994;106:51–61.CrossRefGoogle Scholar
  44. 44.
    Trotta M, Gallarate M, Pattarino F, Carlotti ME. Investigation of the phase behaviour of systems containing lecithin and 2-acyl lysolecithin derivatives. Int J Pharm. 1999;190:83–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Warisnoicharoen W, Lansley AB, Lawrence MJ. Nonionic oil-in-water microemulsions: the effect of oil type on phase behaviour. Int J Pharm. 2000;198:7–27.PubMedCrossRefGoogle Scholar
  46. 46.
    Huibers PD, Shah D. Evidence for synergism in non-ionic surfactant mixtures: enhancement of solubilization in water-in-oil microemulsions. Langmuir. 1997;13:5762–5.CrossRefGoogle Scholar
  47. 47.
    Engels T, Forster T, Rybinsko WV. The influence of coemulsifier type on the stability of oil-in-water emulsions. Colloids Surf A Physicochem Eng Aspects. 1995;99:141–9.CrossRefGoogle Scholar
  48. 48.
    Weingarten C, Magalhaes NSS, Baszkin A, Benita S, Seiller M. Interaction of a nonionic ABA copolymer surfactant with phospholipid monolayers: possible relevance to emulsion stabilization. Int J Pharm. 1991;75:171–9.CrossRefGoogle Scholar
  49. 49.
    Ninham BW, Chen SJ, Evans DF. Role of oils and other factors in microemulsion design. J Phys Chem. 1984;88:5855–7.CrossRefGoogle Scholar
  50. 50.
    Taha MO, Abdel-Halim H, Al-Ghazawi M, Khalil E. QSPR modeling of pseudoternary microemulsions formulated employing lecithin surfactants: application of data mining, molecular and statistical modeling. Int J Pharm. 2005;295:135–55.PubMedCrossRefGoogle Scholar
  51. 51.
    Kawakami K, Yoshikawa T, Hayashi T, Nishihara Y, Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs. II. In vivo study. J Control Release. 2002;81:75–82.PubMedCrossRefGoogle Scholar
  52. 52.
    HaBe A, Keipert S. Development and characterization of microemulsions for ocular application. Eur J Pharm Biopharm. 1997;43:179–83.CrossRefGoogle Scholar
  53. 53.
    Chen H, Chang X, Weng T, Zhao X, Gao Z, Yang Y, et al. A study of microemulsion systems for transdermal delivery of triptolide. J Control Release. 2004;98:427–36.PubMedCrossRefGoogle Scholar
  54. 54.
    Tenjarla S. Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst. 1999;16:461–521.PubMedGoogle Scholar
  55. 55.
    Zignani M, Tabatabay C, Gurny R. Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. Adv Drug Deliv Rev. 1995;16:51–61.CrossRefGoogle Scholar
  56. 56.
    Radomska-Soukharev A, Wojciechowska J. Microemulsions as potential ocular drug delivery systems: phase diagrams and physical properties depending on ingredients. Acta Pol Pharm. 2005;62:465–71.PubMedGoogle Scholar
  57. 57.
    Fialho SL, da Silva-Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol. 2004;32:626–32.PubMedCrossRefGoogle Scholar
  58. 58.
    Ciba-Geigy. Wissenschaftliche Tabellen Geigy. 8th ed. Basel: Ciba-Geigy; 1997. Through Fialho SL, da Silva-Cunha A. New vehicle based on microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol. 2004;32:626-32.Google Scholar
  59. 59.
    Keipert S, Siebenbrodt I, Lüders F, Bornschein M. Mikroemulsionen und ihre. potenzielle pharmazeutische Nutzung. Pharmazie. 1989;44:433–44.PubMedGoogle Scholar
  60. 60.
    Miller D. Measurement of the surface tension of tears. Arch Ophthalmol. 1969;82:368–71.PubMedGoogle Scholar
  61. 61.
    Lin SP, Brenner H. Marangoni convection in a tear film. J Colloid Interface Sci. 1982;85:59–65.CrossRefGoogle Scholar
  62. 62.
    Ciba-Geigy. Wissenschaftliche Tabellen Geigy. 8th ed. Basel: Ciba-Geigy; 1977.Google Scholar
  63. 63.
    Hasse A, Keipert S. Development and characterization of microemulsions for ocular application. Eur J Pharm Biopharm. 1997;43:179–83.CrossRefGoogle Scholar
  64. 64.
    Mathis GA. Clinical ophthalmic pharmacology and therapeutics: ocular drug delivery. In: Gelatt KN, editor. Veterinary ophthalmology. Orlando: Lippincott Williams & Wilkins; 1999. p. 291–7.Google Scholar
  65. 65.
    Van Ooteghem MM. Formulations of ophthalmic solutions and suspensions. Problems and advantages. In: Edman P, editor. Biopharmaceutics of ocular drug delivery. Boca Raton: CRC; 1993. p. 31–2.Google Scholar
  66. 66.
    Polish Pharmaceutical Society. Polish Pharmacopoeia V, vol. 3. Warsaw: Polish Pharmaceutical Society; 1993. p. 39.Google Scholar
  67. 67.
    Terry JE, Hill RM. Human tear osmotic pressure, diurnal variation and closed eye. Arch Ophthalmol. 1978;96:120–2.PubMedGoogle Scholar
  68. 68.
    Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. Int J Pharm. 2001;228:161–70.PubMedCrossRefGoogle Scholar
  69. 69.
    Walters KA, Brain KR, Green DM, James VG, Watkinson AC, Sands RH. Comparison of the transdermal delivery of estradiol from two gel formulations. Maturitas. 1998;29:189–95.PubMedCrossRefGoogle Scholar
  70. 70.
    Lee PJ, Langer R, Shastri VP. Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs. Pharm Res. 2003;20:264–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Roggeband R, York M, Pericoi M, Braun W. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol. 2000;38:727–34.PubMedCrossRefGoogle Scholar
  72. 72.
    Muchtar S, Abdulrazik M, Frucht-Pery J, Benita S. Ex vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea. J Control Release. 1997;44:55–64.CrossRefGoogle Scholar
  73. 73.
    Mainardes RM, Urban MC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC, et al. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets. 2005;6:363–71.PubMedCrossRefGoogle Scholar
  74. 74.
    van der Bijl P, van Eyk AD, Meyer D. Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea. 2001;20:505–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Liu Z, Li J, Nie S, Guo H, Pan W. Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes. J Pharm Pharmacol. 2006;58:45–50.PubMedCrossRefGoogle Scholar
  76. 76.
    Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89–121.PubMedCrossRefGoogle Scholar
  77. 77.
    Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002;28:353–69.PubMedCrossRefGoogle Scholar
  78. 78.
    Yu W, Tabosa do Egito ES, Barratt G, Fessi H, Devissaguet JP, Puisieux F. A novel approach to the preparation of injectable emulsions by a spontaneous emulsification process. Int J Pharm. 1993;89:139–46.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  • Hussein O. Ammar
    • 1
    Email author
  • H. A. Salama
    • 1
  • M. Ghorab
    • 2
  • A. A. Mahmoud
    • 1
  1. 1.Department of Pharmaceutical TechnologyNational Research CenterCairoEgypt
  2. 2.Department of Pharmaceutics, Faculty of PharmacyCairo UniversityCairoEgypt

Personalised recommendations